Skip to main navigation Skip to search Skip to main content

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

  • FIND-CKD investigators
  • University of Groningen
  • Indiana University Bloomington
  • The University of Chicago
  • University Health Network
  • National Heart Centre Singapore
  • Duke-NUS Graduate Medical School
  • University of New South Wales
  • Royal North Shore Hospital
  • Aristotle University of Thessaloniki
  • Providence Inland Northwest Health
  • University of Washington
  • University of Würzburg
  • Bayer AG
  • Bayer Pharmaceuticals

Research output: Contribution to journalArticlepeer-review

76 Scopus citations

Fingerprint

Dive into the research topics of 'Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases